Group 1 - The core announcement is that Beihai Kangcheng (stock code: 1228) plans to raise approximately HKD 200 million through the issuance of new shares, specifically 84,033,613 shares at a subscription price of HKD 2.38, which represents a discount of about 14.7% compared to the previous closing price of HKD 2.79 [1][1][1] - The funds raised will be allocated for operational capital for commercialized products, research and development expenses for existing product lines, and settling trade payables of the group [1][1][1] - After the issuance, the new shares will represent approximately 16.4% of the existing issued share capital and about 14.1% of the enlarged share capital [1][1][1] Group 2 - Beihai Kangcheng is focused on the biopharmaceutical sector, indicating its strategic direction and market positioning [1][1][1] - The issuance is conducted under a general authorization granted by the shareholders' meeting, with completion expected on the fifth business day after all conditions of the subscription agreement are met [1][1][1]
北海康成 ：通過一般授權認購新股份募资约 2.0 亿港元 商業化產品營運資金及註冊維護 現有產...